{
    "hands_on_practices": [
        {
            "introduction": "The distinctions between mutualism, commensalism, and parasitism, while clear in definition, are often points along a dynamic continuum in reality. This first practice moves beyond qualitative labels by asking you to develop a quantitative framework for classifying these interactions. Using a hypothetical set of longitudinal clinical data, you will construct a benefit-cost ratio ($B/C$) that weighs clinical improvements against inflammatory burdens, thereby grounding abstract ecological concepts in measurable patient outcomes. ",
            "id": "4813874",
            "problem": "A clinical cohort study in medical parasitology follows $N=6$ immunocompetent adult hosts quarterly over one year to evaluate a symbiont that can range from mutualist to parasite. At each visit, clinicians record a standardized host clinical index $Y$ (higher is better; $Y$ is a $z$-score), high-sensitivity C-reactive protein (CRP) $I$ in $\\mathrm{mg}/\\mathrm{L}$, and the symbiont colonization status $Z \\in \\{0,1\\}$ (absent or present). Assume that within-host temporal differencing controls for time-invariant host heterogeneity and that remaining time trends are negligible over the averaging windows considered.\n\nFrom each host’s longitudinal record, the following within-host contrasts have been precomputed:\n- For host $i$, $\\Delta Y_i$ is the difference between the within-host mean of $Y$ when $Z=1$ and the within-host mean of $Y$ when $Z=0$.\n- For host $i$, $\\Delta I_i$ is the difference between the within-host mean of $I$ when $Z=1$ and the within-host mean of $I$ when $Z=0$.\n\nYou are tasked to formalize a benefit–cost metric $B/C$ for classifying symbiotic relationships and to estimate it from the data, under the following scientifically grounded assumptions:\n- Host benefit magnitude $B$ is the expected positive part of the host clinical response attributable to the symbiont, $B := \\mathbb{E}\\big[\\max(\\Delta Y,0)\\big]$, measured in standardized $Y$ units.\n- Host cost magnitude $C$ is the expected inflammatory burden attributable to the symbiont, mapped into equivalent $Y$ units via a validated linear calibration $Y \\approx \\alpha + \\beta I$ (estimated independently). Let $\\lambda := -\\beta > 0$ denote the absolute $Y$-unit decrement per $\\mathrm{mg}/\\mathrm{L}$ increase in CRP. Operationally, $C := \\lambda \\,\\mathbb{E}\\big[\\max(\\Delta I,0)\\big]$.\n\nAssume independence across hosts and use the following dataset and calibration constant:\n- $N=6$, with $\\{(\\Delta Y_i,\\Delta I_i)\\}_{i=1}^{6}$ given by\n  - Host $1$: $(\\Delta Y_1,\\Delta I_1)=(0.20,\\,0.80)$\n  - Host $2$: $(\\Delta Y_2,\\Delta I_2)=(0.05,\\,0.10)$\n  - Host $3$: $(\\Delta Y_3,\\Delta I_3)=(-0.10,\\,0.20)$\n  - Host $4$: $(\\Delta Y_4,\\Delta I_4)=(0.15,\\,-0.05)$\n  - Host $5$: $(\\Delta Y_5,\\Delta I_5)=(0.00,\\,0.00)$\n  - Host $6$: $(\\Delta Y_6,\\Delta I_6)=(0.30,\\,0.40)$\n- Calibration $\\lambda = 0.40$ (that is, each $\\mathrm{mg}/\\mathrm{L}$ increase in CRP corresponds to a $0.40$-unit decrease in standardized $Y$).\n\nTasks:\n1) Starting from the core definitions of mutualism, commensalism, and parasitism in medical parasitology (effects on host fitness), define the dimensionless benefit–cost ratio $B/C$ and derive principled estimators $\\widehat{B}$ and $\\widehat{C}$ from the longitudinal contrasts $\\{\\Delta Y_i,\\Delta I_i\\}_{i=1}^{N}$ that are consistent under the assumptions above. Your estimators must be functions of $\\{\\Delta Y_i,\\Delta I_i\\}$ and $\\lambda$ only, and must respect nonnegativity of benefit and cost magnitudes.\n2) Using your estimators, compute $\\widehat{B/C}$ from the provided dataset.\n3) Based on first principles, derive threshold rules that map $B/C>1$ to mutualism, $B/C \\approx 0$ to commensalism (operationally, effects negligible on the measurement scale), and $B/C<1$ to parasitism (costs dominate benefits).\n4) Report the numerical value of $\\widehat{B/C}$ as a unitless number, rounding to four significant figures.",
            "solution": "The user has provided a problem in medical parasitology that requires formalizing a benefit-cost metric for symbiotic relationships, deriving estimators for these quantities, establishing classification rules, and calculating the metric from a given dataset.\n\n### Step 1: Extract Givens\n- Number of hosts: $N=6$.\n- Host clinical index: $Y$ (standardized $z$-score).\n- High-sensitivity C-reactive protein (CRP): $I$ (in units of $\\mathrm{mg}/\\mathrm{L}$).\n- Symbiont colonization status: $Z \\in \\{0, 1\\}$.\n- Within-host contrast for host $i$: $\\Delta Y_i$ is the difference in mean $Y$ between $Z=1$ and $Z=0$ states.\n- Within-host contrast for host $i$: $\\Delta I_i$ is the difference in mean $I$ between $Z=1$ and $Z=0$ states.\n- Host benefit magnitude definition: $B := \\mathbb{E}\\big[\\max(\\Delta Y, 0)\\big]$.\n- Host cost magnitude definition: $C := \\lambda \\,\\mathbb{E}\\big[\\max(\\Delta I, 0)\\big]$.\n- Calibration constant: $\\lambda = 0.40$, representing the absolute decrement in $Y$ per unit increase in $I$.\n- Dataset for $i=1, \\dots, 6$:\n  - $(\\Delta Y_1, \\Delta I_1) = (0.20, 0.80)$\n  - $(\\Delta Y_2, \\Delta I_2) = (0.05, 0.10)$\n  - $(\\Delta Y_3, \\Delta I_3) = (-0.10, 0.20)$\n  - $(\\Delta Y_4, \\Delta I_4) = (0.15, -0.05)$\n  - $(\\Delta Y_5, \\Delta I_5) = (0.00, 0.00)$\n  - $(\\Delta Y_6, \\Delta I_6) = (0.30, 0.40)$\n- Assumptions: Independence across hosts, within-host differencing controls for time-invariant confounders.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, using established concepts from biostatistics, immunology (CRP), and ecology (symbiosis classification). The formulation of benefit as the positive part of a clinical response and cost as the inflammatory burden is a plausible and formalizable model. The problem is well-posed, providing all necessary data, constants, and definitions to derive estimators and compute a numerical result. The language is objective and precise. The data are numerically plausible. There are no internal contradictions, logical fallacies, or ambiguities that would preclude a unique solution. The subtle suggestion of a classification rule for commensalism as $B/C \\approx 0$ is potentially confusing, but the problem asks to *derive* the rules from first principles, which allows for a rigorous and correct interpretation. Therefore, the problem is deemed valid.\n\n### Step 3: Solution\nThe problem is addressed by completing the four specified tasks in logical order.\n\n**Task 1: Define $B/C$ and Derive Estimators $\\widehat{B}$ and $\\widehat{C}$**\n\nThe dimensionless benefit-cost ratio, $B/C$, is defined by the given quantities $B$ and $C$:\n$$\n\\frac{B}{C} = \\frac{\\mathbb{E}\\big[\\max(\\Delta Y, 0)\\big]}{\\lambda \\,\\mathbb{E}\\big[\\max(\\Delta I, 0)\\big]}\n$$\nThe problem requires principled estimators for $B$ and $C$. The pairs $\\{(\\Delta Y_i, \\Delta I_i)\\}_{i=1}^{N}$ represent a sample of $N$ independent observations from the underlying distribution of $(\\Delta Y, \\Delta I)$. The expectation of a function of a random variable, $\\mathbb{E}[g(X)]$, is most naturally estimated by its sample analogue, the sample mean, which is an unbiased and consistent estimator under standard regulatory conditions. This is known as the method of moments.\n\nLet $U = \\max(\\Delta Y, 0)$ and $V = \\max(\\Delta I, 0)$. The quantities to be estimated are $B = \\mathbb{E}[U]$ and $\\mathbb{E}[V]$ (which is a component of $C$).\nThe sample observations for $U$ are $U_i = \\max(\\Delta Y_i, 0)$ and for $V$ are $V_i = \\max(\\Delta I_i, 0)$.\n\nThe estimator for the benefit magnitude, $\\widehat{B}$, is the sample mean of the rectified clinical improvements:\n$$\n\\widehat{B} = \\frac{1}{N} \\sum_{i=1}^N \\max(\\Delta Y_i, 0)\n$$\nThe estimator for the cost magnitude, $\\widehat{C}$, is the calibrated sample mean of the rectified inflammatory burden increases:\n$$\n\\widehat{C} = \\lambda \\left( \\frac{1}{N} \\sum_{i=1}^N \\max(\\Delta I_i, 0) \\right) = \\frac{\\lambda}{N} \\sum_{i=1}^N \\max(\\Delta I_i, 0)\n$$\nThese estimators are functions of the data $\\{\\Delta Y_i, \\Delta I_i\\}$ and the constant $\\lambda$ only. The use of the $\\max(\\cdot, 0)$ function ensures that benefit and cost magnitudes are, by definition, non-negative.\n\n**Task 3: Derive Threshold Rules**\n\nThe classification of a symbiotic relationship depends on the net effect on host fitness. In this model, the net change in host clinical status, expressed in $Y$-units, is the benefit magnitude minus the cost magnitude:\n$$\n\\text{Net Effect} = B - C\n$$\n- **Mutualism**: The host experiences a net benefit. This occurs when $B - C > 0$, or $B > C$. Assuming $C > 0$, dividing by $C$ gives the condition $B/C > 1$. If $C=0$ (no inflammatory cost), any $B > 0$ constitutes a net benefit.\n\n- **Parasitism**: The host experiences a net harm. This occurs when $B - C < 0$, or $B < C$. Assuming $C > 0$, this is equivalent to $B/C < 1$.\n\n- **Commensalism**: The host experiences no net effect. This occurs when $B - C = 0$, or $B = C$. Assuming $C > 0$, this corresponds to $B/C = 1$. A special case of \"true\" commensalism or non-interaction occurs when $B=0$ and $C=0$. In this case, the ratio $B/C$ is indeterminate ($0/0$).\n\nThe classification rules derived from first principles are therefore centered on the threshold value of $1$:\n- $B/C > 1$: Mutualism\n- $B/C = 1$: Commensalism (neutrality)\n- $B/C < 1$: Parasitism\n\nThe case $B/C \\approx 0$ suggested in the prompt corresponds to a scenario where $B \\ll C$, which is a strong form of parasitism where the benefit is negligible compared to the cost.\n\n**Task 2 & 4: Compute $\\widehat{B/C}$ and Report Its Numerical Value**\n\nThe estimator for the ratio $B/C$ is the ratio of the estimators $\\widehat{B}$ and $\\widehat{C}$:\n$$\n\\widehat{B/C} = \\frac{\\widehat{B}}{\\widehat{C}} = \\frac{\\frac{1}{N} \\sum_{i=1}^N \\max(\\Delta Y_i, 0)}{\\frac{\\lambda}{N} \\sum_{i=1}^N \\max(\\Delta I_i, 0)} = \\frac{\\sum_{i=1}^N \\max(\\Delta Y_i, 0)}{\\lambda \\sum_{i=1}^N \\max(\\Delta I_i, 0)}\n$$\nWe use the provided dataset and constants $N=6$ and $\\lambda=0.40$.\n\nFirst, we compute the sum of the rectified benefit terms, $\\sum_{i=1}^{6} \\max(\\Delta Y_i, 0)$:\n$$\n\\sum_{i=1}^{6} \\max(\\Delta Y_i, 0) = \\max(0.20, 0) + \\max(0.05, 0) + \\max(-0.10, 0) + \\max(0.15, 0) + \\max(0.00, 0) + \\max(0.30, 0)\n$$\n$$\n= 0.20 + 0.05 + 0 + 0.15 + 0 + 0.30 = 0.70\n$$\nFrom this, the estimated benefit magnitude is $\\widehat{B} = 0.70/6$.\n\nNext, we compute the sum of the rectified cost-related terms, $\\sum_{i=1}^{6} \\max(\\Delta I_i, 0)$:\n$$\n\\sum_{i=1}^{6} \\max(\\Delta I_i, 0) = \\max(0.80, 0) + \\max(0.10, 0) + \\max(0.20, 0) + \\max(-0.05, 0) + \\max(0.00, 0) + \\max(0.40, 0)\n$$\n$$\n= 0.80 + 0.10 + 0.20 + 0 + 0 + 0.40 = 1.50\n$$\nFrom this, the estimated cost magnitude is $\\widehat{C} = \\lambda \\times (1.50/6) = 0.40 \\times (1.50/6) = 0.60/6 = 0.10$.\n\nNow, we compute the estimated ratio $\\widehat{B/C}$:\n$$\n\\widehat{B/C} = \\frac{\\sum_{i=1}^6 \\max(\\Delta Y_i, 0)}{\\lambda \\sum_{i=1}^6 \\max(\\Delta I_i, 0)} = \\frac{0.70}{0.40 \\times 1.50} = \\frac{0.70}{0.60} = \\frac{7}{6}\n$$\nAs a decimal, this is $7 \\div 6 \\approx 1.1666...$.\n\nFinally, rounding to four significant figures as requested:\n$$\n\\widehat{B/C} \\approx 1.167\n$$\nSince $\\widehat{B/C} \\approx 1.167 > 1$, the data suggest that the symbiotic relationship is, on average, mutualistic, with the clinical benefits slightly outweighing the inflammatory costs.",
            "answer": "$$\\boxed{1.167}$$"
        },
        {
            "introduction": "The role of a microbe as a harmless commensal or a harmful parasite can depend heavily on the host's condition, a common dilemma in immunocompromised patients. This exercise simulates a high-stakes clinical scenario where you must decide whether to treat a potential pathogen under uncertainty. By applying expected utility theory, you will derive a precise probability threshold, $p^*$, for initiating therapy, learning how to systematically balance the benefits of treatment against the risks of toxicity. ",
            "id": "4813893",
            "problem": "A protozoan commonly considered a commensal is detected in the stool of an immunocompromised patient with fever and diarrhea. In immunocompetent hosts, this organism is typically a harmless commensal, but in immunocompromised hosts it may act parasitically and cause invasive disease. The clinician must decide whether to initiate empiric antiparasitic therapy now or to defer treatment and monitor. Model this decision under uncertainty by defining the posterior probability $p$ that, in this particular patient, the organism is acting parasitically (that is, is the cause of disease) rather than remaining a harmless commensal. Use the expected utility principle, which states that the expected utility (or expected loss) of an action is the probability-weighted sum of the utilities (or losses) of its possible outcomes, to construct a decision rule.\n\nAssume the following scientifically grounded quantities:\n- If the organism is acting parasitically and no treatment is given, the expected health loss is $L = 150$ Quality-Adjusted Life Days (QALDs), where Quality-Adjusted Life Days (QALDs) quantify time adjusted for health-related quality of life.\n- If treatment is given and the organism is acting parasitically, treatment efficacy reduces disease burden by a proportion $e = 0.8$, leaving a residual disease loss of $(1 - e)L$.\n- Treatment has independent toxicity with two components: a mild, near-certain disutility $d_{m} = 3$ QALDs and a serious adverse event that occurs with probability $q = 0.02$ and carries an additional disutility $d_{s} = 50$ QALDs. These toxicities apply regardless of whether the organism is acting parasitically.\n- If the organism is not acting parasitically (that is, it remains a commensal and is not the cause of disease), then in the absence of treatment there is no disease-related loss, and with treatment there is only toxicity.\n\nUsing only the expected utility principle and the core definitions of symbiotic roles (commensal versus parasitic), derive the threshold posterior probability $p^{*}$ at which the expected loss from immediate treatment equals the expected loss from deferring treatment. Then compute the numerical value of $p^{*}$ for the parameter values above. Provide your final threshold as an exact value. State any intermediate expressions you use, but your final reported answer must be a single exact number or a single closed-form expression with no units. If you choose to also compute a decimal approximation for your own verification, do not report it as your final answer.",
            "solution": "The problem presents a classical decision analysis scenario under uncertainty, framed within a medical context. The decision is whether to treat a patient empirically for a potential parasitic infection. The organism in question exhibits a dual role: it can be a harmless commensal or a pathogenic parasite, particularly in an immunocompromised host. The decision will be made by comparing the expected losses of two possible actions: immediate treatment versus deferring treatment. We are asked to find the threshold posterior probability, denoted $p^{*}$, at which these two expected losses are equal.\n\nFirst, let us formalize the problem. Let the state of nature be represented by a random variable $S$. There are two possible states:\n$S=P$: The organism is acting parasitically, causing the patient's symptoms. The probability of this state is given as $p$, so $\\text{Pr}(S=P) = p$.\n$S=C$: The organism is a harmless commensal, and the symptoms have another cause. The probability of this state is $\\text{Pr}(S=C) = 1-p$.\n\nThere are two possible actions:\nAction $T$: Treat with antiparasitic therapy.\nAction $D$: Defer treatment and monitor.\n\nThe goal is to calculate the expected loss for each action and find the probability $p^{*}$ where the expected losses are equivalent. Loss is quantified in Quality-Adjusted Life Days (QALDs).\n\nThe given parameters are:\n-   Loss from untreated parasitic disease: $L = 150$.\n-   Treatment efficacy: $e = 0.8$.\n-   Mild disutility from treatment: $d_{m} = 3$.\n-   Probability of a serious adverse event from treatment: $q = 0.02$.\n-   Additional disutility from a serious adverse event: $d_{s} = 50$.\n\nFirst, let us calculate the total expected loss associated with treatment toxicity, $L_{\\text{tox}}$. This loss is incurred if and only if treatment is given, regardless of the state of nature. It consists of a certain mild disutility and an expected disutility from a potential serious adverse event.\n$$L_{\\text{tox}} = d_{m} + q \\cdot d_{s}$$\n\nNow, we will formulate the expected loss for each action. The expected loss is the sum of the losses of each possible outcome, weighted by their respective probabilities.\n\nLet $E[\\text{Loss}(T)]$ be the expected loss of Action $T$ (Treat).\nThe loss depends on the true state of nature.\nIf the state is $S=P$ (probability $p$), the patient has the disease. Treatment reduces the disease loss $L$ by a factor of $e$. The residual disease loss is $(1-e)L$. Additionally, the patient incurs the treatment toxicity loss, $L_{\\text{tox}}$. The total loss in this branch is $(1-e)L + L_{\\text{tox}}$.\nIf the state is $S=C$ (probability $1-p$), the patient does not have the parasitic disease, so the disease-related loss is $0$. However, the patient still incurs the treatment toxicity loss, $L_{\\text{tox}}$. The total loss in this branch is $L_{\\text{tox}}$.\n\nCombining these, the expected loss for treating is:\n$$E[\\text{Loss}(T)] = p \\cdot [(1-e)L + L_{\\text{tox}}] + (1-p) \\cdot L_{\\text{tox}}$$\n$$E[\\text{Loss}(T)] = p(1-e)L + p \\cdot L_{\\text{tox}} + L_{\\text{tox}} - p \\cdot L_{\\text{tox}}$$\n$$E[\\text{Loss}(T)] = p(1-e)L + L_{\\text{tox}}$$\nSubstituting the expression for $L_{\\text{tox}}$:\n$$E[\\text{Loss}(T)] = p(1-e)L + d_{m} + q \\cdot d_{s}$$\n\nNext, let $E[\\text{Loss}(D)]$ be the expected loss of Action $D$ (Defer).\nIf the state is $S=P$ (probability $p$), the patient has the disease and goes untreated. The loss is $L$. There is no treatment toxicity.\nIf the state is $S=C$ (probability $1-p$), the patient does not have the parasitic disease and is not treated. The loss is $0$.\n\nCombining these, the expected loss for deferring treatment is:\n$$E[\\text{Loss}(D)] = p \\cdot L + (1-p) \\cdot 0$$\n$$E[\\text{Loss}(D)] = pL$$\n\nThe threshold probability $p^{*}$ is the value of $p$ for which the decision-maker is indifferent between the two actions. This occurs when their expected losses are equal:\n$$E[\\text{Loss}(T)] = E[\\text{Loss}(D)]$$\nSubstituting the expressions we derived for the expected losses at $p = p^{*}$:\n$$p^{*}(1-e)L + d_{m} + q \\cdot d_{s} = p^{*}L$$\n\nWe now solve this equation for $p^{*}$.\n$$d_{m} + q \\cdot d_{s} = p^{*}L - p^{*}(1-e)L$$\n$$d_{m} + q \\cdot d_{s} = p^{*}[L - (1-e)L]$$\n$$d_{m} + q \\cdot d_{s} = p^{*}[L - L + eL]$$\n$$d_{m} + q \\cdot d_{s} = p^{*}(eL)$$\n$$p^{*} = \\frac{d_{m} + q \\cdot d_{s}}{eL}$$\n\nThis expression for $p^{*}$ is the treatment threshold. It represents the ratio of the expected harm of treatment (the numerator, $L_{\\text{tox}}$) to the net benefit of treatment for a diseased patient (the denominator, which is the amount of loss averted, $L - (1-e)L = eL$). If the clinician's posterior probability $p$ is greater than this threshold $p^{*}$, the expected loss of deferring is greater than the expected loss of treating, so treatment is the optimal choice. If $p < p^{*}$, deferring is optimal.\n\nNow, we substitute the given numerical values into the expression for $p^{*}$:\n$L = 150$, $e = 0.8$, $d_{m} = 3$, $q = 0.02$, and $d_{s} = 50$.\n\nFirst, calculate the numerator:\n$$d_{m} + q \\cdot d_{s} = 3 + (0.02) \\cdot (50) = 3 + 1 = 4$$\n\nNext, calculate the denominator:\n$$eL = (0.8) \\cdot (150) = \\frac{4}{5} \\cdot 150 = 4 \\cdot 30 = 120$$\n\nFinally, compute the threshold probability $p^{*}$:\n$$p^{*} = \\frac{4}{120}$$\n$$p^{*} = \\frac{1}{30}$$\nThe computed value is an exact fraction, as required.",
            "answer": "$$\\boxed{\\frac{1}{30}}$$"
        },
        {
            "introduction": "An emerging frontier in medicine involves actively engineering the host's microbiome to prevent or treat disease. This final practice explores such a proactive strategy, where probiotic therapy is used to reinforce the resident commensal population to suppress a pathogen through colonization resistance. You will use a mathematical model combining population dynamics and epidemiology to determine the minimum therapeutic dose needed to lower the pathogen's effective reproduction number, $R_{\\mathrm{eff}}$, below the critical threshold of one and halt an outbreak. ",
            "id": "4813885",
            "problem": "In a hospital outbreak of a parasitic enteric pathogen, restoring gut commensalism via probiotic therapy is proposed to lower the pathogen's effective reproduction number, defined as the expected number of secondary cases per infectious case in the current population. In medical parasitology, symbiotic relationships include mutualism (both partners benefit), commensalism (one benefits, the other is unaffected), and parasitism (one benefits at the expense of the other). Probiotics aim to restore commensalism and colonization resistance, a well-tested phenomenon where established commensal bacteria reduce pathogen transmission by occupying ecological niches and modulating host immunity.\n\nAssume the baseline basic reproduction number is $R_{0}$ and that colonization resistance reduces the transmission proportional to the fraction of gut microbial carrying capacity occupied by commensals. Specifically, suppose the effective reproduction number satisfies\n$$\nR_{\\mathrm{eff}} = R_{0} \\left(1 - \\theta \\frac{C}{K}\\right),\n$$\nwhere $C$ is the commensal biomass, $K$ is the carrying capacity, and $\\theta \\in (0,1]$ quantifies the efficiency of commensal occupancy in reducing pathogen transmission. The probiotic dosing regimen is modeled by a constant daily input of colony-forming units, with conversion efficiency such that a fraction $\\sigma$ of administered colony-forming units (CFU) becomes established in the gut. The commensal biomass dynamics are modeled by logistic growth with washout and exogenous input:\n$$\n\\frac{dC}{dt} = r C \\left(1 - \\frac{C}{K}\\right) - \\delta C + \\sigma D,\n$$\nwhere $r$ is the intrinsic growth rate (per day), $\\delta$ is the washout or loss rate (per day), and $D$ is the constant dosing rate in colony-forming units per day (CFU/day). At steady state, the commensal biomass is $C^{*}$, the positive equilibrium of this differential equation.\n\nStarting from the core definitions of the basic reproduction number and colonization resistance, and from the above dynamical model for commensal restoration, derive an expression for the minimal constant dosing rate $D^{*}$ that ensures $R_{\\mathrm{eff}} < 1$. Then, using the parameter values\n- $R_{0} = 2.2$,\n- $\\theta = 0.9$,\n- $K = 1.0 \\times 10^{11}$ CFU,\n- $r = 0.6$ day$^{-1}$,\n- $\\delta = 0.35$ day$^{-1}$,\n- $\\sigma = 0.02$ (dimensionless),\n\ncompute the numerical value of $D^{*}$. Express the dosing rate in colony-forming units per day (CFU/day). Round your answer to three significant figures.",
            "solution": "The user has requested that I validate the problem statement before solving it.\n\n### Step 1: Extract Givens\n- Effective reproduction number: $R_{\\mathrm{eff}} = R_{0} \\left(1 - \\theta \\frac{C}{K}\\right)$\n- Commensal biomass dynamics: $\\frac{dC}{dt} = r C \\left(1 - \\frac{C}{K}\\right) - \\delta C + \\sigma D$\n- Condition for disease control: $R_{\\mathrm{eff}} < 1$\n- Definition of steady-state commensal biomass: $C^{*}$, the positive equilibrium of the differential equation.\n- Definition of minimal dosing rate: $D^{*}$ is the minimal constant dosing rate that ensures $R_{\\mathrm{eff}} < 1$.\n- Basic reproduction number: $R_{0} = 2.2$\n- Commensal occupancy efficiency: $\\theta = 0.9$\n- Gut microbial carrying capacity: $K = 1.0 \\times 10^{11}$ CFU\n- Commensal intrinsic growth rate: $r = 0.6$ day$^{-1}$\n- Commensal washout/loss rate: $\\delta = 0.35$ day$^{-1}$\n- Probiotic conversion efficiency: $\\sigma = 0.02$ (dimensionless)\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, using standard models from epidemiology (reproduction number) and population ecology (logistic growth with source/sink terms). The concept of colonization resistance mediated by commensal microbiota is a valid principle in medical microbiology. The problem is well-posed, providing sufficient information and a clear objective. The parameters are specified, and the language is objective and unambiguous. The model is a simplification of a complex biological system but is logically and mathematically consistent for the purposes of the problem. No flaws are identified.\n\n### Step 3: Verdict and Action\nThe problem is valid. A solution will be provided.\n\n### Solution Derivation\n\nThe primary goal is to find the minimal constant dosing rate, $D^{*}$, required to reduce the effective reproduction number, $R_{\\mathrm{eff}}$, to a value less than $1$. The solution proceeds in three main steps:\n1.  Determine the critical steady-state commensal biomass, $C_{crit}^{*}$, needed to achieve $R_{\\mathrm{eff}} = 1$.\n2.  Establish the relationship between the dosing rate, $D$, and the steady-state commensal biomass, $C^{*}$, from the given dynamical equation.\n3.  Use this relationship to calculate the minimal dosing rate, $D^{*}$, that produces the critical biomass $C_{crit}^{*}$.\n\nFirst, we establish the condition for controlling the pathogen outbreak. Control is achieved when each infectious case produces, on average, fewer than one new case, which is mathematically stated as $R_{\\mathrm{eff}} < 1$. The minimal requirement corresponds to the boundary condition $R_{\\mathrm{eff}} = 1$. Let $C_{crit}^{*}$ be the commensal biomass at which this threshold is met. Substituting the given expression for $R_{\\mathrm{eff}}$:\n$$ R_{0} \\left(1 - \\theta \\frac{C_{crit}^{*}}{K}\\right) = 1 $$\nWe solve for the critical biomass, $C_{crit}^{*}$:\n$$ 1 - \\theta \\frac{C_{crit}^{*}}{K} = \\frac{1}{R_{0}} $$\n$$ \\theta \\frac{C_{crit}^{*}}{K} = 1 - \\frac{1}{R_{0}} $$\n$$ C_{crit}^{*} = \\frac{K}{\\theta} \\left(1 - \\frac{1}{R_{0}}\\right) $$\nAny biomass $C^{*} > C_{crit}^{*}$ will result in $R_{\\mathrm{eff}} < 1$.\n\nSecond, we determine the steady-state commensal biomass, $C^{*}$, as a function of the probiotic dosing rate, $D$. The steady state is achieved when the rate of change of the biomass is zero, i.e., $\\frac{dC}{dt} = 0$. Using the provided differential equation:\n$$ 0 = r C^{*} \\left(1 - \\frac{C^{*}}{K}\\right) - \\delta C^{*} + \\sigma D $$\nWe can rearrange this equation to solve for the term $\\sigma D$ that corresponds to a given steady state $C^{*}$:\n$$ \\sigma D = \\delta C^{*} - r C^{*} \\left(1 - \\frac{C^{*}}{K}\\right) $$\n$$ \\sigma D = \\delta C^{*} - r C^{*} + \\frac{r}{K}(C^{*})^2 $$\n$$ \\sigma D = \\frac{r}{K}(C^{*})^2 - (r - \\delta)C^{*} $$\nThis equation gives the required input $\\sigma D$ to maintain a steady-state biomass of $C^{*}$. Since the relationship between $C^{*}$ and $D$ is monotonic for the positive equilibrium solution, the minimal dosing rate $D^{*}$ will be the rate that achieves exactly the critical biomass $C_{crit}^{*}$.\n\nThird, we calculate $D^{*}$ by substituting the expression for $C_{crit}^{*}$ into the steady-state equation.\n$$ \\sigma D^{*} = \\frac{r}{K}(C_{crit}^{*})^2 - (r - \\delta)C_{crit}^{*} $$\nFactoring out $C_{crit}^{*}$:\n$$ D^{*} = \\frac{C_{crit}^{*}}{\\sigma} \\left( \\frac{r}{K}C_{crit}^{*} - (r - \\delta) \\right) $$\nNow, we substitute the expression for $C_{crit}^{*} = \\frac{K}{\\theta} \\left(1 - \\frac{1}{R_{0}}\\right)$:\n$$ D^{*} = \\frac{1}{\\sigma} \\left[ \\frac{K}{\\theta} \\left(1 - \\frac{1}{R_{0}}\\right) \\right] \\left[ \\frac{r}{K} \\left( \\frac{K}{\\theta} \\left(1 - \\frac{1}{R_{0}}\\right) \\right) - (r - \\delta) \\right] $$\nSimplifying the term in the second bracket:\n$$ D^{*} = \\frac{K}{\\sigma\\theta} \\left(1 - \\frac{1}{R_{0}}\\right) \\left[ \\frac{r}{\\theta} \\left(1 - \\frac{1}{R_{0}}\\right) - (r - \\delta) \\right] $$\nThis is the final analytical expression for the minimal dosing rate $D^{*}$.\n\nNow, we substitute the given numerical values:\n- $R_{0} = 2.2$\n- $\\theta = 0.9$\n- $K = 1.0 \\times 10^{11}$\n- $r = 0.6$ day$^{-1}$\n- $\\delta = 0.35$ day$^{-1}$\n- $\\sigma = 0.02$\n\nWe compute the required terms:\n- $1 - \\frac{1}{R_{0}} = 1 - \\frac{1}{2.2} = 1 - \\frac{5}{11} = \\frac{6}{11}$\n- $r - \\delta = 0.6 - 0.35 = 0.25$\n- $\\frac{r}{\\theta} = \\frac{0.6}{0.9} = \\frac{2}{3}$\n\nSubstitute these into the expression for $D^{*}$:\n$$ D^{*} = \\frac{1.0 \\times 10^{11}}{(0.02)(0.9)} \\left( \\frac{6}{11} \\right) \\left[ \\frac{2}{3} \\left( \\frac{6}{11} \\right) - 0.25 \\right] $$\n$$ D^{*} = \\frac{1.0 \\times 10^{11}}{0.018} \\left( \\frac{6}{11} \\right) \\left[ \\frac{4}{11} - \\frac{1}{4} \\right] $$\n$$ D^{*} = \\frac{1.0 \\times 10^{11}}{0.018} \\left( \\frac{6}{11} \\right) \\left[ \\frac{16 - 11}{44} \\right] $$\n$$ D^{*} = \\frac{1.0 \\times 10^{11}}{0.018} \\left( \\frac{6}{11} \\right) \\left( \\frac{5}{44} \\right) $$\n$$ D^{*} = \\frac{1.0 \\times 10^{11}}{0.018} \\left( \\frac{30}{484} \\right) $$\nNow, we calculate the numerical value:\n$$ D^{*} = \\left( \\frac{1.0 \\times 10^{11}}{0.018} \\right) \\times \\left( \\frac{30}{484} \\right) \\approx (5.555... \\times 10^{12}) \\times (0.06198...) $$\n$$ D^{*} \\approx 3.443526 \\times 10^{11} $$\nThe problem requires the answer to be rounded to three significant figures.\n$$ D^{*} \\approx 3.44 \\times 10^{11} $$\nThe units are colony-forming units per day (CFU/day), as confirmed by dimensional analysis:\n$$ [D^{*}] = \\frac{[\\text{CFU}]}{[\\text{dimensionless}]} \\times [\\text{dimensionless}] \\times [\\text{day}^{-1}] = \\text{CFU}/\\text{day} $$",
            "answer": "$$ \\boxed{3.44 \\times 10^{11}} $$"
        }
    ]
}